BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 2015;54:961-70. [PMID: 25984930 DOI: 10.3109/0284186X.2015.1043026] [Cited by in Crossref: 107] [Cited by in F6Publishing: 70] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 James JL, Balko JM. Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1. Curr Breast Cancer Rep 2019;11:217-27. [PMID: 33312343 DOI: 10.1007/s12609-019-00331-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Akcay M, Etiz D, Celik O, Ozen A. Evaluation of Prognosis in Nasopharyngeal Cancer Using Machine Learning. Technol Cancer Res Treat 2020;19:1533033820909829. [PMID: 32138606 DOI: 10.1177/1533033820909829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wu J, You K, Chen C, Zhong H, Jiang Y, Mo H, Song J, Qiu X, Liu Y. High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer. Front Oncol 2021;11:641682. [PMID: 33777804 DOI: 10.3389/fonc.2021.641682] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen Y, Wen S, Xia J, Du X, Wu Y, Pan B, Zhu W, Shen B. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer. Front Immunol 2021;12:672271. [PMID: 34054853 DOI: 10.3389/fimmu.2021.672271] [Reference Citation Analysis]
5 Van Wilpe S, Koornstra R, Den Brok M, De Groot JW, Blank C, De Vries J, Gerritsen W, Mehra N. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology 2020;9:1731942. [PMID: 32158624 DOI: 10.1080/2162402X.2020.1731942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
6 Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Br J Cancer 2021;124:115-23. [PMID: 33204029 DOI: 10.1038/s41416-020-01159-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Terlizzi M, Molino A, Colarusso C, Somma P, De Rosa I, Troisi J, Scala G, Salvi R, Pinto A, Sorrentino R. Altered lung tissue lipidomic profile in caspase-4 positive non-small cell lung cancer (NSCLC) patients. Oncotarget 2020;11:3515-25. [PMID: 33014287 DOI: 10.18632/oncotarget.27724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Naik PP. Role of Biomarkers in the Integrated Management of Melanoma. Dis Markers 2021;2021:6238317. [PMID: 35003391 DOI: 10.1155/2021/6238317] [Reference Citation Analysis]
9 Li L, Ai L, Jia L, Zhang L, Lei B, Zhang Q. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine. BMC Cancer 2022;22:29. [PMID: 34980025 DOI: 10.1186/s12885-021-09131-6] [Reference Citation Analysis]
10 Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget 2017;8:95853-64. [PMID: 29221172 DOI: 10.18632/oncotarget.21401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kiran D, Basaraba RJ. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review. Front Cell Infect Microbiol 2021;11:624607. [PMID: 33718271 DOI: 10.3389/fcimb.2021.624607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Castello A, Toschi L, Rossi S, Mazziotti E, Lopci E. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. J Cancer Res Clin Oncol 2020;146:1235-43. [PMID: 32048008 DOI: 10.1007/s00432-020-03150-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
13 Ma L, Qiu J, Zhang Y, Qiu T, Wang B, Chen W, Li X, Sun J, Wang K, Li X, Gu Y, Shu Y, Chen X. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. Onco Targets Ther 2018;11:2533-43. [PMID: 29765232 DOI: 10.2147/OTT.S150502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tan P, Chen J, Xie N, Xu H, Ai J, Xu H, Liu L, Yang L, Wei Q. Is preoperative serum lactate dehydrogenase useful in predicting the outcomes of patients with upper tract urothelial carcinoma? Cancer Med 2018;7:5096-106. [PMID: 30151961 DOI: 10.1002/cam4.1751] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
15 Yin S, Li Z, Huang J, Miao Z, Zhang J, Lu C, Xu H, Xu H. Prognostic value and clinicopathological significance of proliferating cell nuclear antigen expression in gastric cancer: a systematic review and meta-analysis. Onco Targets Ther 2017;10:319-27. [PMID: 28138255 DOI: 10.2147/OTT.S126551] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lacerenza S, Ciregia F, Giusti L, Bonotti A, Greco V, Giannaccini G, D'Antongiovanni V, Fallahi P, Pieroni L, Cristaudo A, Lucacchini A, Mazzoni MR, Foddis R. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome. Cancer Genomics Proteomics 2020;17:225-36. [PMID: 32345664 DOI: 10.21873/cgp.20183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
17 Ke J, Chen Y, Wang X, Wu Z, Zhang Q, Lian Y, Chen F. Machine learning-based in-hospital mortality prediction models for patients with acute coronary syndrome. Am J Emerg Med 2022;53:127-34. [PMID: 35033770 DOI: 10.1016/j.ajem.2021.12.070] [Reference Citation Analysis]
18 Neuwinger N, Meyer Zum Büschenfelde D, Tauber R, Kappert K. Underfilling of vacuum blood collection tubes leads to increased lactate dehydrogenase activity in serum and heparin plasma samples. Clin Chem Lab Med 2020;58:213-21. [PMID: 31665108 DOI: 10.1515/cclm-2019-0616] [Reference Citation Analysis]
19 Tjokrowidjaja A, Lord SJ, John T, Lewis CR, Kok PS, Marschner IC, Lee CK. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. Cancer 2022. [PMID: 35090047 DOI: 10.1002/cncr.34113] [Reference Citation Analysis]
20 Wang W, Huang Z, Yu Z, Zhuang W, Zheng W, Cai Z, Shi L, Yu X, Lou G, Hong W, Zhang Y, Chen M, Song Z. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. Front Oncol 2020;10:572853. [PMID: 33163403 DOI: 10.3389/fonc.2020.572853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Odan N, Kikawa Y, Matsumoto H, Minohata J, Suwa H, Hashimoto T, Okuno T, Miyashita M, Saito M, Yamagami K, Takao S. Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study. Breast Cancer (Auckl) 2020;14:1178223420983843. [PMID: 33447040 DOI: 10.1177/1178223420983843] [Reference Citation Analysis]
22 Roshandel E, Parkhideh S, Ghaffari Nazari H, Mehdizadeh M, Bonakchi H, Sankanian G, Hajifathali A. Pre-and Post-Transplant Serum Lactate Dehydrogenase Levels as a Predictive Marker for Patient Survival and Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Rep Biochem Mol Biol 2021;10:204-15. [PMID: 34604410 DOI: 10.52547/rbmb.10.2.204] [Reference Citation Analysis]
23 Aday U, Tatlı F, Akpulat FV, İnan M, Kafadar MT, Bilge H, Başol Ö, Oğuz A. Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer. Contemp Oncol (Pozn) 2020;24:145-9. [PMID: 33235539 DOI: 10.5114/wo.2020.100219] [Reference Citation Analysis]
24 Zou J, Li Q, Kou F, Zhu Y, Lu M, Li J, Lu Z, Shen L. Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours. Curr Oncol. 2019;26:e30-e38. [PMID: 30853807 DOI: 10.3747/co.26.4135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Aday U, Böyük A, Akkoç H. The prognostic significance of serum lactate dehydrogenase-to-albumin ratio in colorectal cancer. Ann Surg Treat Res 2020;99:161-70. [PMID: 32908848 DOI: 10.4174/astr.2020.99.3.161] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, Nicolardi L, Caglio A, Aerts S, Cortellini A, Ficorella C, Chiari R, Di Maio M, Dingemans AC, Aerts JGJV, Berardi R. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. J Clin Med 2021;10:1005. [PMID: 33801320 DOI: 10.3390/jcm10051005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Truelsen CG, Serup-Hansen E, Storm KS, Havelund BM, Kronborg CS, Spindler KG. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study. Cancer Med 2021;10:3224-30. [PMID: 33960701 DOI: 10.1002/cam4.3886] [Reference Citation Analysis]
28 Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M, Fuereder T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med 2022;54:1339-49. [PMID: 35535695 DOI: 10.1080/07853890.2022.2070660] [Reference Citation Analysis]
29 Li H, An X, Huang R, Li L, Chu C, Yang W, Qin Z, Liu Z, Zhou F, Xue C, Shi Y. Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy. Front Mol Biosci 2021;8:621883. [PMID: 34458319 DOI: 10.3389/fmolb.2021.621883] [Reference Citation Analysis]
30 Liu YT, Zhang K, Li CC, Hu XS, Jiang J, Hao XZ, Wang Y, Li JL, Xing PY, Yang S, Zhang X, Wang GQ, Cai SL, Shi YK. Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI. J Cancer 2019;10:5108-13. [PMID: 31602263 DOI: 10.7150/jca.33450] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Liu Y, Zhou YP, Zhang M, Li L, Liao H, Ma L, Lin F, Chen YY, Fu CX, Huang TT, Lu Y, Zhang Y. Clinicopathologic Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer. J Oncol 2021;2021:7722231. [PMID: 34976059 DOI: 10.1155/2021/7722231] [Reference Citation Analysis]
32 Galland L, Le Page AL, Lecuelle J, Bibeau F, Oulkhouir Y, Derangère V, Truntzer C, Ghiringhelli F. Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. Oncoimmunology 2021;10:1957603. [PMID: 34377595 DOI: 10.1080/2162402X.2021.1957603] [Reference Citation Analysis]
33 Guimarães TA, Farias LC, Santos ES, de Carvalho Fraga CA, Orsini LA, de Freitas Teles L, Feltenberger JD, de Jesus SF, de Souza MG, Santos SH, de Paula AM, Gomez RS, Guimarães AL. Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma. Oncotarget 2016;7:55057-68. [PMID: 27474170 DOI: 10.18632/oncotarget.10842] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
34 Hansen TF, Nederby L, Zedan AH, Mejlholm I, Henriksen JR, Steffensen KD, Thomsen CB, Raunkilde L, Jensen LH, Jakobsen A. Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. Transl Oncol 2019;12:968-72. [PMID: 31103777 DOI: 10.1016/j.tranon.2019.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
35 Song P, Yang D, Cui X, Wang H, Si X, Zhang X, Zhang L. NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. Cancer Manag Res 2020;12:5975-85. [PMID: 32765097 DOI: 10.2147/CMAR.S257967] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM. Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. Am J Clin Dermatol 2020;21:1-11. [PMID: 31602560 DOI: 10.1007/s40257-019-00475-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity 2019;50:477-492.e8. [PMID: 30737146 DOI: 10.1016/j.immuni.2019.01.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 17.0] [Reference Citation Analysis]
38 Kubota H, Soejima T, Sulaiman NS, Sekii S, Matsumoto Y, Ota Y, Tsujino K, Fujita I, Fujimoto T, Morishita M, Ikegaki J, Matsumoto K, Sasaki R. Predicting the survival of patients with bone metastases treated with radiation therapy: a validation study of the Katagiri scoring system. Radiat Oncol 2019;14:13. [PMID: 30658673 DOI: 10.1186/s13014-019-1218-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
39 Baltazar F, Afonso J, Costa M, Granja S. Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy. Front Oncol 2020;10:231. [PMID: 32257942 DOI: 10.3389/fonc.2020.00231] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
40 Jia Z, Zhang J, Wang Z, Wang B, Wang L, Cao J, Tao Z, Hu X. An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. Oncotarget 2018;9:10714-22. [PMID: 29535837 DOI: 10.18632/oncotarget.24246] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
41 Ayano M, Arinobu Y, Tsukamoto H, Ota SI, Misaki K, Nishimura K, Kimoto Y, Mitoma H, Akahoshi M, Akashi K, Horiuchi T, Niiro H. Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica. Rheumatol Int 2020;40:1101-9. [PMID: 32062696 DOI: 10.1007/s00296-020-04512-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Ma T, Wu Z, Zhang X, Xu H, Feng Y, Zhang C, Xie M, Yang Y, Zhang Y, Feng C, Sun G. Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma. BMC Cancer 2021;21:1326. [PMID: 34895168 DOI: 10.1186/s12885-021-09079-7] [Reference Citation Analysis]
43 Olaoba OT, Kadasah S, Vetter SW, Leclerc E. RAGE Signaling in Melanoma Tumors. Int J Mol Sci 2020;21:E8989. [PMID: 33256110 DOI: 10.3390/ijms21238989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 He K, Chen C, Xia L, Si L, Pan X, Sun Z, Wang Y, Jiang Y, Shi Y, Zhou B, Wang S, Han J, Shen B, Zhou G, Lu J, Wang X. Deep muscularis propria tumor invasion without lymph node metastasis as a unique subclassification of stage IB gastric cancer: a retrospective study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-021-02090-z] [Reference Citation Analysis]
45 Bopp T, Schild H. [Immunological foundations of modern (tumor) immunotherapy]. Pathologe 2018;39:492-7. [PMID: 30327859 DOI: 10.1007/s00292-018-0517-8] [Reference Citation Analysis]
46 Qi J, Gu C, Wang W, Xiang M, Chen X, Fu J. Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin's Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation. Front Oncol 2021;11:753712. [PMID: 34778068 DOI: 10.3389/fonc.2021.753712] [Reference Citation Analysis]
47 Lv W, Shang H, Pei X, Chen Y, Xie H, He D, Wang X, Li L. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. Int Urol Nephrol 2017;49:61-7. [PMID: 27837416 DOI: 10.1007/s11255-016-1456-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
48 Wang Z, Zhao X, Gao C, Gong J, Wang X, Gao J, Li Z, Wang J, Yang B, Wang L, Zhang B, Zhou Y, Wang D, Li X, Bai Y, Li J, Shen L. Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment. J Immunother Cancer 2020;8:e001297. [PMID: 33172882 DOI: 10.1136/jitc-2020-001297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zhao C, Li LQ, Yang FD, Wei RL, Wang MK, Song DX, Guo XY, Du W, Wei XT. A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma. Front Oncol 2020;10:591352. [PMID: 33363021 DOI: 10.3389/fonc.2020.591352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Li C, Shi M, Lin X, Zhang Y, Yu S, Zhou C, Yang N, Zhang J, Zhang F, Lv T, Liu H, Song Y. Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. Transl Lung Cancer Res 2021;10:776-89. [PMID: 33718021 DOI: 10.21037/tlcr-20-832] [Reference Citation Analysis]
51 Mishra D, Banerjee D. Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment. Cancers (Basel) 2019;11:E750. [PMID: 31146503 DOI: 10.3390/cancers11060750] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 22.7] [Reference Citation Analysis]
52 Chen HY, Larson PEZ, Bok RA, von Morze C, Sriram R, Delos Santos R, Delos Santos J, Gordon JW, Bahrami N, Ferrone M, Kurhanewicz J, Vigneron DB. Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion. Cancer Res 2017;77:3207-16. [PMID: 28428273 DOI: 10.1158/0008-5472.CAN-16-2083] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 10.2] [Reference Citation Analysis]
53 Iwasa S, Kudo T, Takahari D, Hara H, Kato K, Satoh T. Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol 2020;25:1223-32. [PMID: 32347434 DOI: 10.1007/s10147-020-01684-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
54 Jelinek D, Flores A, Uebelhoer M, Pasque V, Plath K, Iruela-Arispe ML, Christofk HR, Lowry WE, Coller HA. Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp 2018. [PMID: 29985359 DOI: 10.3791/57760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
55 Thomas C, Bögemann M, König F, Machtens S, Schostak M, Steuber T, Heidenreich A. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel]. Urologe A 2016;55:772-82. [PMID: 26820660 DOI: 10.1007/s00120-016-0030-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
56 Trigg RM, Shaw JA, Turner SD. Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biol 2019;9:190056. [PMID: 31088252 DOI: 10.1098/rsob.190056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
57 Majeed H, Amir E. Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. J Thorac Dis 2018;10:S995-8. [PMID: 29849197 DOI: 10.21037/jtd.2018.03.153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Huang W, Liu P, Zong M, Chen QQ, Zhou H, Kong H, Xie WP. Combining Lactate Dehydrogenase and Fibrinogen: Potential Factors to Predict Therapeutic Efficacy and Prognosis of Patients with Small-Cell Lung Cancer. Cancer Manag Res 2021;13:4299-307. [PMID: 34103985 DOI: 10.2147/CMAR.S300153] [Reference Citation Analysis]
59 Hu M, Li Y, Lu Y, Wang M, Li Y, Wang C, Li Q, Zhao H. The regulation of immune checkpoints by the hypoxic tumor microenvironment. PeerJ 2021;9:e11306. [PMID: 34012727 DOI: 10.7717/peerj.11306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2018;4:351-7. [PMID: 29327044 DOI: 10.1001/jamaoncol.2017.4771] [Cited by in Crossref: 232] [Cited by in F6Publishing: 276] [Article Influence: 77.3] [Reference Citation Analysis]
61 Ke L, Wang L, Yu J, Meng X. Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study. Front Oncol 2021;11:652312. [PMID: 34094942 DOI: 10.3389/fonc.2021.652312] [Reference Citation Analysis]
62 Zhang Z, Li Y, Yan X, Song Q, Wang G, Hu Y, Jiao S, Wang J. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Cancer Med 2019;8:1467-73. [PMID: 30848091 DOI: 10.1002/cam4.2024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 13.7] [Reference Citation Analysis]
63 Pelizzari G, Basile D, Zago S, Lisanti C, Bartoletti M, Bortot L, Vitale MG, Fanotto V, Barban S, Cinausero M, Bonotto M, Gerratana L, Mansutti M, Curcio F, Fasola G, Minisini AM, Puglisi F. Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers (Basel) 2019;11:E1243. [PMID: 31450641 DOI: 10.3390/cancers11091243] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
64 Yuan ZY, Gao SG, Mu JW, Xue Q, Mao YS, Wang DL, Zhao J, Gao YS, Huang JF, He J. Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma. J Thorac Dis 2016;8:2464-72. [PMID: 27746998 DOI: 10.21037/jtd.2016.08.56] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
65 Li F, Zhang W, Hu H, Zhang Y, Li J, Huang D. Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases. Cancer Manag Res 2022;14:107-22. [PMID: 35023974 DOI: 10.2147/CMAR.S343648] [Reference Citation Analysis]
66 Zhao C, Li L, Guo X, Song D, Wang M, Zhai Y, Yang F, Xue Y, Wei X. Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy. Cancer Manag Res 2021;13:1159-68. [PMID: 33603461 DOI: 10.2147/CMAR.S290053] [Reference Citation Analysis]
67 Lewis R, Habringer S, Kircher M, Hefter M, Peuker CA, Werner R, Ademaj-Kospiri V, Gäble A, Weber W, Wester HJ, Buck A, Herhaus P, Lapa C, Keller U. Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res 2021;11:77. [PMID: 34417915 DOI: 10.1186/s13550-021-00822-6] [Reference Citation Analysis]
68 Cheng B, Wang C, Zou B, Huang D, Yu J, Cheng Y, Meng X. A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators. Cancer Med 2020;9:1430-40. [PMID: 31899603 DOI: 10.1002/cam4.2805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Lin GS, Huang XY, Lu J, Wu D, Zheng HL, Xu BB, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Lin GT, Huang ZN, Lin JL, Huang CM. A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients. Surg Endosc 2021. [PMID: 34076769 DOI: 10.1007/s00464-021-08461-7] [Reference Citation Analysis]
70 Beielstein AC, Pallasch CP. Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy. Int J Mol Sci 2019;20:E4158. [PMID: 31454887 DOI: 10.3390/ijms20174158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
71 Wang J, Li L, Dong BQ, Xu YJ, Zheng YD, Sun ZW, Yang Y, Chen YY, Chen XZ, Chen M. Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma. Oncotarget 2016;7:27458-67. [PMID: 27050275 DOI: 10.18632/oncotarget.8480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer 2022. [PMID: 35460066 DOI: 10.1007/s12282-022-01357-x] [Reference Citation Analysis]
73 Wen SWC, Andersen RF, Hansen TF, Nyhus CH, Hager H, Hilberg O, Jakobsen A. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. Transl Lung Cancer Res 2021;10:855-65. [PMID: 33718027 DOI: 10.21037/tlcr-20-826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol 2021. [PMID: 34110489 DOI: 10.1007/s00432-021-03672-w] [Reference Citation Analysis]
75 Luo HS, Xu HY, Du ZS, Li XY, Wu SX, Huang HC, Lin LX. Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy. Front Oncol 2020;10:430. [PMID: 32351882 DOI: 10.3389/fonc.2020.00430] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Guo S, Wu X, Pei J, Wang X, Bao P, Xiong L, Chu M, Liang C, Yan P, Guo X. Genome-wide CNV analysis reveals variants associated with high-altitude adaptation and meat traits in Qaidam cattle. Electronic Journal of Biotechnology 2021;54:8-16. [DOI: 10.1016/j.ejbt.2021.07.006] [Reference Citation Analysis]
77 Janka EA, Várvölgyi T, Sipos Z, Soós A, Hegyi P, Kiss S, Dembrovszky F, Csupor D, Kéringer P, Pécsi D, Solymár M, Emri G. Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:772165. [PMID: 34950582 DOI: 10.3389/fonc.2021.772165] [Reference Citation Analysis]
78 Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M. Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer 2015;113:1389-96. [PMID: 26469834 DOI: 10.1038/bjc.2015.361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
79 Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, Kumar SK, Gertz MA. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol 2017;178:888-95. [PMID: 28699650 DOI: 10.1111/bjh.14830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
80 Wang ZX, Yang LP, Qiu MZ, Wang ZQ, Zhou YX, Wang F, Zhang DS, Wang FH, Li YH, Xu RH. Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms. Oncotarget 2016;7:39945-56. [PMID: 27223065 DOI: 10.18632/oncotarget.9459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
81 Ippolito JE, Yim AK, Luo J, Chinnaiyan P, Rubin JB. Sexual dimorphism in glioma glycolysis underlies sex differences in survival. JCI Insight 2017;2:92142. [PMID: 28768910 DOI: 10.1172/jci.insight.92142] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
82 Hui D, Dev R, Pimental L, Park M, Cerana MA, Liu D, Bruera E. Association Between Multi-frequency Phase Angle and Survival in Patients With Advanced Cancer. J Pain Symptom Manage 2017;53:571-7. [PMID: 28042079 DOI: 10.1016/j.jpainsymman.2016.09.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
83 Huang H, Li S, Tang Q, Zhu G. Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma. Front Immunol 2021;12:680955. [PMID: 34566954 DOI: 10.3389/fimmu.2021.680955] [Reference Citation Analysis]
84 Chen Z, Guo Q, Lu T, Lin S, Zong J, Zhan S, Xu L, Pan J. Pretreatment Serum Lactate Dehydrogenase Level as an Independent Prognostic Factor of Nasopharyngeal Carcinoma in the Intensity-Modulated Radiation Therapy Era. Med Sci Monit 2017;23:437-45. [PMID: 28120819 DOI: 10.12659/msm.899531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
85 Li L, Wang Y, He X, Li Z, Lu M, Gong T, Chang Q, Lin J, Liu C, Luo Y, Min L, Zhou Y, Tu C. Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma. Front Immunol 2022;13:879560. [DOI: 10.3389/fimmu.2022.879560] [Reference Citation Analysis]
86 Untereiner AA, Oláh G, Módis K, Hellmich MR, Szabo C. H2S-induced S-sulfhydration of lactate dehydrogenase a (LDHA) stimulates cellular bioenergetics in HCT116 colon cancer cells. Biochem Pharmacol 2017;136:86-98. [PMID: 28404377 DOI: 10.1016/j.bcp.2017.03.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
87 Criscitiello C, Marra A, Morganti S, Zagami P, Viale G, Esposito A, Curigliano G. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. Oncologist 2020;25:e1732-42. [PMID: 32785940 DOI: 10.1634/theoncologist.2020-0518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
88 Hevia D, Gonzalez-Menendez P, Fernandez-Fernandez M, Cueto S, Rodriguez-Gonzalez P, Garcia-Alonso JI, Mayo JC, Sainz RM. Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A 13C Stable Isotope-Resolved Metabolomic Study. Int J Mol Sci 2017;18:E1620. [PMID: 28933733 DOI: 10.3390/ijms18081620] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]